Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (930)	12/12/1997 9:14:00 AM
From: Pancho Villa	Read Replies (1) \| Respond to of 1359

Neuro: after reading your post and the press release from the company yesterday, I feel so confident that IPIC has no liability and that no further negative news will develop, that I have decided to cover my remaining short position [at a profit] today. In addition, I will sell my long positions in LLY, CNTO, NEO, and put it all in IPIC stock. At under $10 this puppy is a bargain! regards, Pancho

To: NeuroInvestment who wrote (930)	12/12/1997 12:34:00 PM
From: (no name provided)	Read Replies (2) \| Respond to of 1359

Neuroinvestment, Your logic is slightly flawed. If you read the WSJ article, then you would realize that this was NOT a echocardiographic study of a large group of Redux/Pondimin users. These were merely initial case reports of valvular pathology in diet pill users. Of course, they are short 3,299,970. But by the same logic as you use above, there would be no AIDS epidemic. The first case reports were less than 10 gay men with immune deficiency. Just as those cases were the tip of the iceberg, the Belgian cases were probably just the first. Look, IPIC has some great potential in the other projects, but they fell into a quagmire. This is no longer investment-grade stock. You are a smart guy from what I tell of your postings. But you are defending a sunken ship. Cut your losses and retain your credibility. Kafka666